Product Name

  • Name

    Omeprazole

  • EINECS 201-212-8
  • CAS No. 73590-58-6
  • Article Data76
  • CAS DataBase
  • Density 1.371 g/cm3
  • Solubility Easily soluble in dichloromethane, chloroform and methanol
  • Melting Point 156 °C
  • Formula C17H19N3O3S
  • Boiling Point 599.991 °C at 760 mmHg
  • Molecular Weight 345.422
  • Flash Point 316.663 °C
  • Transport Information
  • Appearance white crystalline solid
  • Safety 26-36-37/39
  • Risk Codes 36/37/38
  • Molecular Structure Molecular Structure of 73590-58-6 (Omeprazole)
  • Hazard Symbols IrritantXi
  • Synonyms Pepticus;Zoltum;Lensor;Pepticum;Indurgan;1H-Benzimidazole,5-methoxy-2-[[(4-methoxy- 3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-;Prilosec (TN);Omerprazole;Omisec;Gibancer;Prazidec;Ulzol;Omezolan;Ulsen;Ortanol;Victrix;Omeprazon;Omapren;Zimor;Procelac;Dudencer;5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole;Proclor;Antra;Omesek;Omeprol;Mopral;Gasec;Peptilcer;Nopramin;Tedec Ulceral;Omid;Zegerid;Result;Ulcesep;Gastroloc;Losec;Ompanyt;2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole;Omed;Prilosec OTC;Antra MUPS;Omeprazolum [INN-Latin];Omebeta 20;Omizac;Zepral;Demeprazol;Ozoken;Omegast;Zefxon;Omeprazol [INN-Spanish];Danlox;Ceprandal;Olexin;Belmazol;Ulcometion;Erbolin;Miracid;Osiren;Prazolit;Ulcozol;Inhipump;Nilsec;Exter;Regulacid;
  • PSA 96.31000
  • LogP 3.76540

Synthetic route

2-(chloromethyl)-4-methoxy-3,5-dimethylpyridine hydrochloride
86604-75-3

2-(chloromethyl)-4-methoxy-3,5-dimethylpyridine hydrochloride

6-methoxy-1H-benzoimidazole-2-thiol
37052-78-1

6-methoxy-1H-benzoimidazole-2-thiol

omeprazole
73590-58-6

omeprazole

Conditions
ConditionsYield
Stage #1: 6-methoxy-1H-benzoimidazole-2-thiol With sodium hydroxide In ethanol; water at 70 - 90℃;
Stage #2: 2-(chloromethyl)-4-methoxy-3,5-dimethylpyridine hydrochloride With hydrogenchloride In ethanol; water at -10 - 30℃; for 4h; Reflux;
96%
omeprazole sulfide
73590-85-9

omeprazole sulfide

omeprazole
73590-58-6

omeprazole

Conditions
ConditionsYield
With dihydrogen peroxide; molybdenyl acetylacetonate In methanol; water at 0 - 5℃; for 3h;91%
With dihydrogen peroxide; sodium carbonate; sodium tungstate In methanol; water at 20℃; for 0.666667h; Product distribution / selectivity;91%
With sodium hydroxide; dihydrogen peroxide; sodium tungstate In methanol; water at 20℃; for 0.666667h; Product distribution / selectivity;88%
(-)-menthyl 5-methoxy-2-benzimidazolylsulphinate
1080503-61-2

(-)-menthyl 5-methoxy-2-benzimidazolylsulphinate

2,3,5-trimethyl-4-methoxypyridine
109371-19-9

2,3,5-trimethyl-4-methoxypyridine

omeprazole
73590-58-6

omeprazole

Conditions
ConditionsYield
Stage #1: 4-methoxy-2,3,5-trimethylpyridine With n-butyllithium In tetrahydrofuran at -90 - -80℃; for 0.5h;
Stage #2: (-)-menthyl 5-methoxy-2-benzimidazolylsulphinate In tetrahydrofuran at -80 - -20℃;
Stage #3: With water In tetrahydrofuran at -20℃;
86%
phthalic anhydride
85-44-9

phthalic anhydride

5-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridinyl)methylthio]-1H-benzimidazole hydrochloride

5-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridinyl)methylthio]-1H-benzimidazole hydrochloride

omeprazole
73590-58-6

omeprazole

Conditions
ConditionsYield
With sodium hydroxide; dihydrogen peroxide; sodium carbonate In water; 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran85.9%
omeprazole sulfide
73590-85-9

omeprazole sulfide

A

omeprazole
73590-58-6

omeprazole

B

omeprazole sulphone

omeprazole sulphone

Conditions
ConditionsYield
With oxone; sodium hydrogencarbonate; bis(acetylacetonate)oxovanadium In methanol; water at -2 - 0℃; for 5.5h;A 84%
B n/a
With oxone; sodium hydrogencarbonate In methanol; water at 0℃; for 5.5h;A 84%
B 0.15%
With oxone; sodium hydrogencarbonate In methanol; tetrabutylammomium bromide; water at -2 - 3℃; for 7.5h; Product distribution / selectivity;A 84%
B n/a
aqueous sodium metabisulphate

aqueous sodium metabisulphate

(acac)2

(acac)2

aqueous tert-butyl hydroperoxide (TBHP)

aqueous tert-butyl hydroperoxide (TBHP)

omeprazole sulfide
73590-85-9

omeprazole sulfide

omeprazole
73590-58-6

omeprazole

Conditions
ConditionsYield
In ethanol79%
C10H12N2O3S

C10H12N2O3S

(chloromethyl)-4-methoxy-3,5-dimethylpyridine
84006-10-0

(chloromethyl)-4-methoxy-3,5-dimethylpyridine

A

C18H24N2O2

C18H24N2O2

B

omeprazole
73590-58-6

omeprazole

Conditions
ConditionsYield
Stage #1: (chloromethyl)-4-methoxy-3,5-dimethylpyridine With [Mg(anthracene)(THF)3] In tetrahydrofuran at -5 - 0℃; Inert atmosphere;
Stage #2: C10H12N2O3S In tetrahydrofuran at -5 - 30℃; for 4h; Inert atmosphere;
A n/a
B 30%
omeprazole sulfide
73590-85-9

omeprazole sulfide

A

omeprazole
73590-58-6

omeprazole

B

8-methoxy-2,4-dimethyl-5-thioxo-5-hydro-pyrido<1',2':3,4>imidazo<1,2-a>benzimidazol-3-one

8-methoxy-2,4-dimethyl-5-thioxo-5-hydro-pyrido<1',2':3,4>imidazo<1,2-a>benzimidazol-3-one

C

omeprazole sulphone

omeprazole sulphone

Conditions
ConditionsYield
With potassium sulfate; potassium hydrogensulfate; potassium peroxomonosulfate In ethanol; acetate buffer at -5℃; pH=5.0; Oxidation; cyclization;
5-methoxy-2-[[(4-methoxy-3,5-dimethylpyridin-2-yl-1-oxide)methyl]sulfanyl]-1H-benzimidazole
142885-92-5

5-methoxy-2-[[(4-methoxy-3,5-dimethylpyridin-2-yl-1-oxide)methyl]sulfanyl]-1H-benzimidazole

omeprazole
73590-58-6

omeprazole

Conditions
ConditionsYield
With iodobenzene; silver(I) acetate; Ru(III)(N,N'-bis(salicylidene)-o-phenylenediamine)(triphenylphosphine)Cl In dichloromethane Heating / reflux;
With iodobenzene; silver(I) acetate; Ru(III)(salen)(PPh3)Cl In dichloromethane Heating / reflux;
aqueous sodium metabisulphite

aqueous sodium metabisulphite

omeprazole sulfide
73590-85-9

omeprazole sulfide

omeprazole
73590-58-6

omeprazole

Conditions
ConditionsYield
With tert.-butylhydroperoxide; VO(acac)2 In toluene
concentrated acetic acid

concentrated acetic acid

Diethyl tartrate
408332-88-7

Diethyl tartrate

omeprazole sulfide
73590-85-9

omeprazole sulfide

A

racemic omeprazole

racemic omeprazole

B

omeprazole
73590-58-6

omeprazole

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine; isopropylbenzene hydroperoxide; titanium(IV) isopropylate In 2,2,4-trimethylpentane; water; ethyl acetate; acetone
concentrated acetic acid

concentrated acetic acid

diethyl (2S,3S)-tartrate
13811-71-7

diethyl (2S,3S)-tartrate

omeprazole sulfide
73590-85-9

omeprazole sulfide

A

racemic omeprazole

racemic omeprazole

B

omeprazole
73590-58-6

omeprazole

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine; isopropylbenzene hydroperoxide; titanium(IV) isopropylate In 2,2,4-trimethylpentane; water; ethyl acetate; acetone; acetonitrile
diisopropylethyl amine
861359-74-2

diisopropylethyl amine

Diethyl tartrate
408332-88-7

Diethyl tartrate

omeprazole sulfide
73590-85-9

omeprazole sulfide

omeprazole
73590-58-6

omeprazole

Conditions
ConditionsYield
With isopropylbenzene hydroperoxide; titanium(IV) isopropylate In water; toluene
Diethyl tartrate
408332-88-7

Diethyl tartrate

omeprazole sulfide
73590-85-9

omeprazole sulfide

omeprazole
73590-58-6

omeprazole

Conditions
ConditionsYield
With potassium hydrogencarbonate; isopropylbenzene hydroperoxide; titanium(IV) isopropylate In water; ethyl acetate
With isopropylbenzene hydroperoxide; titanium(IV) isopropylate In dichloromethane; water
With isopropylbenzene hydroperoxide; titanium(IV) isopropylate In dichloromethane; water
With isopropylbenzene hydroperoxide; titanium(IV) isopropylate In water; toluene
diethyl (2S,3S)-tartrate
13811-71-7

diethyl (2S,3S)-tartrate

omeprazole sulfide
73590-85-9

omeprazole sulfide

omeprazole
73590-58-6

omeprazole

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine; isopropylbenzene hydroperoxide; titanium(IV) isopropylate In toluene
Sodium perborate 4H2O

Sodium perborate 4H2O

omeprazole sulfide
73590-85-9

omeprazole sulfide

omeprazole
73590-58-6

omeprazole

Conditions
ConditionsYield
With acetic anhydride In methanol; water; toluene
amoxicillin
26787-78-0

amoxicillin

omeprazole
73590-58-6

omeprazole

(S)-5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (R)-1,1'-binaphthyl-2,2'-diyl hydrogen phosphate

(S)-5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (R)-1,1'-binaphthyl-2,2'-diyl hydrogen phosphate

omeprazole
73590-58-6

omeprazole

Conditions
ConditionsYield
With sodium hydrogencarbonate In ethyl acetate at 5 - 10℃; for 0.5h;
2-(chloromethyl)-4-methoxy-3,5-dimethylpyridine hydrochloride
86604-75-3

2-(chloromethyl)-4-methoxy-3,5-dimethylpyridine hydrochloride

omeprazole
73590-58-6

omeprazole

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: sodium hydroxide / methanol / 5 h / Reflux
2.1: diethyl (2S,3S)-tartrate; titanium propoxide / water; toluene / 1 h / 80 °C
2.2: 1.5 h / 30 °C
View Scheme
2-Mercapto-5-methoxybenzimidazole
37052-78-1

2-Mercapto-5-methoxybenzimidazole

omeprazole
73590-58-6

omeprazole

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: sodium hydroxide / methanol / 5 h / Reflux
2.1: diethyl (2S,3S)-tartrate; titanium propoxide / water; toluene / 1 h / 80 °C
2.2: 1.5 h / 30 °C
View Scheme
acetonitrile-chloroform

acetonitrile-chloroform

chloroform methanol
7285-11-2

chloroform methanol

omeprazole
73590-58-6

omeprazole

sodium phosphate

sodium phosphate

1-benzensulfonyl-5-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole

1-benzensulfonyl-5-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole

Conditions
ConditionsYield
With triethylamine; benzenesulfonyl chloride; sodium chloride In n-heptane; dichloromethane95%
omeprazole
73590-58-6

omeprazole

isopropylamine
75-31-0

isopropylamine

5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, magnesium salt

5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, magnesium salt

Conditions
ConditionsYield
With magnesium sulfate In methanol; water95%
In methanol; water92%
(S)-[1,1']-binaphthalenyl-2,2'-diol
18531-99-2

(S)-[1,1']-binaphthalenyl-2,2'-diol

omeprazole
73590-58-6

omeprazole

esomeprazole (S)-(-)-binol complex

esomeprazole (S)-(-)-binol complex

Conditions
ConditionsYield
In dichloromethane; di-isopropyl ether at 20 - 25℃; for 4.58333h; Solvent; Temperature;94.9%
choline chloride
67-48-1

choline chloride

omeprazole
73590-58-6

omeprazole

5-methoxy-2-(4-methoxy-3,5-dimethylpyridin-2-ylmethanesulfinyl)-1H-benzoimidazole choline salt

5-methoxy-2-(4-methoxy-3,5-dimethylpyridin-2-ylmethanesulfinyl)-1H-benzoimidazole choline salt

Conditions
ConditionsYield
With sodium hydroxide In ethanol at 20℃; for 24h;94%
(S)-[1,1']-binaphthalenyl-2,2'-diol
18531-99-2

(S)-[1,1']-binaphthalenyl-2,2'-diol

omeprazole
73590-58-6

omeprazole

S-omeprazole*(S)-[1.1'-binaphthalen]-2.2'-diol inclusion complex

S-omeprazole*(S)-[1.1'-binaphthalen]-2.2'-diol inclusion complex

Conditions
ConditionsYield
With triethylamine In n-heptane; toluene at 70℃; for 0.5h; Product distribution / selectivity;94%
With triethylamine In toluene at 70℃; for 0.5h; Product distribution / selectivity;89%
With ammonia In water; isopropyl alcohol at 50 - 60℃; Product distribution / selectivity;89%
omeprazole
73590-58-6

omeprazole

omeprazole sodium

omeprazole sodium

Conditions
ConditionsYield
With sodium hydroxide In methanol; isopropyl alcohol at 20℃; for 2h;92.8%
With sodium hydroxide In water; isopropyl alcohol at 20℃; for 0.666667h;84.5%
With sodium hydroxide In dichloromethane; water at 20℃; for 0.0833333h;60%
(S)-1,1,2-triphenyl-1,2-ethanediol
108998-83-0

(S)-1,1,2-triphenyl-1,2-ethanediol

omeprazole
73590-58-6

omeprazole

(S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole [(S)-1,1,2-triphenyl-1,2-ethanediol]2

(S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole [(S)-1,1,2-triphenyl-1,2-ethanediol]2

Conditions
ConditionsYield
In n-heptane; toluene at 20 - 100℃; for 1h; Product distribution / selectivity;91%
In ethanol at 20℃; for 30h; Product distribution / selectivity;90%
In toluene at 20 - 90℃; for 1 - 18h; Product distribution / selectivity;87%
diethylzinc
557-20-0

diethylzinc

omeprazole
73590-58-6

omeprazole

esomeprazole zinc
912968-18-4, 565431-48-3

esomeprazole zinc

Conditions
ConditionsYield
In tetrahydrofuran; hexane at 20℃;91%
omeprazole
73590-58-6

omeprazole

omeprazole magnesium

omeprazole magnesium

Conditions
ConditionsYield
With magnesium hydroxide In tetrahydrofuran; water at 20 - 25℃;90%
With magnesium methanolate In methanol
With magnesium In methanol; dichloromethane at 5 - 30℃; for 1 - 1.25h; Product distribution / selectivity;
Mg(NO3)2

Mg(NO3)2

omeprazole
73590-58-6

omeprazole

isopropylamine
75-31-0

isopropylamine

5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, magnesium salt

5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, magnesium salt

Conditions
ConditionsYield
In methanol; water89%
omeprazole
73590-58-6

omeprazole

5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1H-benzimidazole

5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1H-benzimidazole

Conditions
ConditionsYield
With titanium(IV) isopropylate; diethyl (2S,3S)-tartrate; Cumene hydroperoxide; N-ethyl-N,N-diisopropylamine In water; ethyl acetate at 20 - 34℃; for 3.5h;82%
C28H43ClO2

C28H43ClO2

omeprazole
73590-58-6

omeprazole

C45H61N3O5S

C45H61N3O5S

Conditions
ConditionsYield
In dichloromethane at 0 - 20℃; Inert atmosphere;80%
omeprazole
73590-58-6

omeprazole

diethylamine
109-89-7

diethylamine

5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, magnesium salt

5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, magnesium salt

Conditions
ConditionsYield
With MgCl2 In methanol; water76%
(S)-[1,1']-binaphthalenyl-2,2'-diol
18531-99-2

(S)-[1,1']-binaphthalenyl-2,2'-diol

omeprazole
73590-58-6

omeprazole

R-omeprazole-(S)-[1,1'-binaphthalen]-2,2'-diol inclusion complex

R-omeprazole-(S)-[1,1'-binaphthalen]-2,2'-diol inclusion complex

S-omeprazole*(S)-[1.1'-binaphthalen]-2.2'-diol inclusion complex

S-omeprazole*(S)-[1.1'-binaphthalen]-2.2'-diol inclusion complex

Conditions
ConditionsYield
In hexane; benzene at 90℃; for 0.5h; Product distribution / selectivity;A n/a
B 76%
In hexane; benzene at 90℃; for 0.5h; Product distribution / selectivity;A n/a
B 76 %Chromat.
omeprazole
73590-58-6

omeprazole

esomeprazole
119141-88-7

esomeprazole

Conditions
ConditionsYield
Stage #1: omeprazole With titanium(IV) isopropylate; diethyl (2S,3S)-tartrate; water; triethylamine In acetone at 35 - 40℃; Large scale;
Stage #2: With (S)-Mandelic acid In acetone at 35 - 40℃; for 2h; Large scale;
Stage #3: With sodium hydrogencarbonate In dichloromethane; water for 0.5h; Large scale;
73%
enantiomeric resolution; inclusion complexation with (S)-(-)-2,2'-dihydroxy-1,1'-binaphthyl;
With diethylamine In methanol Purification / work up; Chiral high performance liquid chromatography; Resolution of racemate;
1-Adamantanamine
768-94-5

1-Adamantanamine

omeprazole
73590-58-6

omeprazole

5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole 1-adamantan ammonium salt

5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole 1-adamantan ammonium salt

Conditions
ConditionsYield
In methanol; acetonitrile at 20 - 50℃; for 2h;73%
omeprazole
73590-58-6

omeprazole

5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, magnesium salt

5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, magnesium salt

Conditions
ConditionsYield
With aqueous NH3; magnesium sulfate In methanol; water71%
omeprazole
73590-58-6

omeprazole

omeprazole sulfide
73590-85-9

omeprazole sulfide

Conditions
ConditionsYield
With tris(pentafluorophenyl)borate; phenylsilane In toluene at 60℃; for 8h; Inert atmosphere; Schlenk technique; Green chemistry;71%
omeprazole
73590-58-6

omeprazole

esomeprazole sodium salt

esomeprazole sodium salt

Conditions
ConditionsYield
With sodium hydroxide In ethanol for 2h; Reflux;70%
Multi-step reaction with 2 steps
1.1: N-ethyl-N,N-diisopropylamine / dmap / dichloromethane / 0.5 h / 5 - 10 °C
1.2: 5 - 10 °C
1.3: pH 6.5 - 7
2.1: sodium hydroxide / methanol / 13.5 h / 0 - 25 °C
View Scheme
iron(III) chloride hexahydrate

iron(III) chloride hexahydrate

omeprazole
73590-58-6

omeprazole

[Fe(5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole)2(H2O)2]Cl3*2H2O

[Fe(5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole)2(H2O)2]Cl3*2H2O

Conditions
ConditionsYield
In methanol at 20℃; for 3h;65%
cobalt(II) chloride hexahydrate

cobalt(II) chloride hexahydrate

omeprazole
73590-58-6

omeprazole

[Co(H2O)2(5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole)2]Cl2*H2O

[Co(H2O)2(5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole)2]Cl2*H2O

Conditions
ConditionsYield
In N,N-dimethyl-formamide; acetone at 20℃; for 3h;60%
xanthene
92-83-1

xanthene

omeprazole
73590-58-6

omeprazole

5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1-(9H-xant hen-9-yl)-1H-benzo[d]imidazole

5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1-(9H-xant hen-9-yl)-1H-benzo[d]imidazole

Conditions
ConditionsYield
With methanesulfonic acid; tetrabutylammonium tetrafluoroborate In acetonitrile at 20℃; for 2h; Electrochemical reaction;48%

Omeprazole Specification

The Omeprazole, with the CAS registry number 73590-58-6, is also known as 2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole. It belongs to the product categories of Drug bulk; Active Pharmaceutical Ingredients; Omeprazole; Intermediates & Fine Chemicals; Pharmaceuticals; API's; ATPase. Its EINECS number is 200-636-0. This chemical's molecular formula is C17H19N3O3S and molecular weight is 345.42. What's more, its systematic name is 6-Methoxy-2-{[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl}-1H-benzimidazole. Its classification codes are: (1)Anti-ulcer agents; (2)Depressant [gastric acid secretory]; (3)Drug / Therapeutic Agent; (4)Enzyme inhibitors; (5)Gastrointestinal Agents; (6)Human Data; (7)Mutation data; (8)Reproductive Effect. This chemical is a proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD), laryngopharyngeal reflux (LPR) and Zollinger–Ellison syndrome. Omeprazole is one of the most widely prescribed drugs internationally and is available over the counter in some countries. This chemical should be sealed and stored in a cool and dry place. Moreover, it should be protected from oxides.

Physical properties of Omeprazole are: (1)ACD/LogP: 2.452; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): 2.39; (4)ACD/LogD (pH 7.4): 2.44; (5)ACD/BCF (pH 5.5): 37.10; (6)ACD/BCF (pH 7.4): 41.57; (7)ACD/KOC (pH 5.5): 443.46; (8)ACD/KOC (pH 7.4): 496.87; (9)#H bond acceptors: 6; (10)#H bond donors: 1; (11)#Freely Rotating Bonds: 5; (12)Polar Surface Area: 96.31 Å2; (13)Index of Refraction: 1.669; (14)Molar Refractivity: 94.021 cm3; (15)Molar Volume: 251.869 cm3; (16)Polarizability: 37.273×10-24cm3; (17)Surface Tension: 75.2 dyne/cm; (18)Density: 1.371 g/cm3; (19)Flash Point: 316.663 °C; (20)Enthalpy of Vaporization: 89.315 kJ/mol; (21)Boiling Point: 599.991 °C at 760 mmHg; (22)Vapour Pressure: 0 mmHg at 25°C.

When you are using this chemical, please be cautious about it as the following:
This chemical is irritating to eyes, respiratory system and skin. In case of contact with eyes, you should rinse immediately with plenty of water and seek medical advice. When using it, you need wear suitable protective clothing, gloves and eye/face protection.

Mechanism of action of Omeprazole: it is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell. By acting specifically on the proton pump, omeprazole blocks the final step in acid production, thus reducing gastric acidity.

Pharmacokinetics of Omeprazole: The absorption of omeprazole takes place in the small intestine and is usually completed within 3–6 hours. The systemic bioavailability of omeprazole after repeated dose is about 60%. Omeprazole bioavailability is significantly impaired by the presence of food and, therefore, patients should be advised to take omeprazole with a glass of water on an empty stomach (i.e., fast for at least 60 minutes before taking omeprazole). Additionally, most sources recommend that after taking omeprazole at least 30 minutes should be allowed to elapse before eating (at least 60 minutes for immediate-release omeprazole plus sodium bicarbonate products, such as Zegerid), though some sources say that with delayed-release forms of omeprazole it is not necessary to wait before eating after taking the medication. Plasma protein binding is about 95%. Omeprazole is completely metabolized by the cytochrome P450 system, mainly in the liver. Identified metabolites are the sulfone, the sulfide and hydroxy-omeprazole, which exert no significant effect on acid secretion. About 80% of an orally given dose is excreted as metabolites in the urine and the remainder is found in the feces, primarily originating from bile secretion.

You can still convert the following datas into molecular structure:
(1)SMILES: O=S(c2nc1ccc(OC)cc1n2)Cc3ncc(c(OC)c3C)C
(2)Std. InChI: InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)
(3)Std. InChIKey: SUBDBMMJDZJVOS-UHFFFAOYSA-N

The toxicity data is as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LD50 unreported > 600mg/kg (600mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 33, Pg. 782, 1991.
man TDLo oral 4mg/kg/2W-I (4mg/kg) MUSCULOSKELETAL: JOINTS Lancet. Vol. 345, Pg. 461, 1995.
mouse LD50 intraperitoneal > 100mg/kg (100mg/kg)   Oyo Yakuri. Pharmacometrics. Vol. 36, Pg. 369, 1988.
mouse LD50 intraperitoneal > 100mg/kg (100mg/kg) SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE

SKIN AND APPENDAGES (SKIN): HAIR: OTHER
Oyo Yakuri. Pharmacometrics. Vol. 36, Pg. 369, 1988.
mouse LD50 intravenous 82800ug/kg (82.8mg/kg)   Scandinavian Journal of Gastroenterology, Supplement. Vol. 108, Pg. 53, 1985.
mouse LD50 oral > 4gm/kg (4000mg/kg) BEHAVIORAL: ATAXIA

LUNGS, THORAX, OR RESPIRATION: DYSPNEA

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Oyo Yakuri. Pharmacometrics. Vol. 36, Pg. 369, 1988.
mouse LD50 subcutaneous > 100mg/kg (100mg/kg) SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"
Oyo Yakuri. Pharmacometrics. Vol. 36, Pg. 369, 1988.
rat LD50 intraperitoneal > 100mg/kg (100mg/kg) LUNGS, THORAX, OR RESPIRATION: DYSPNEA

SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
Oyo Yakuri. Pharmacometrics. Vol. 36, Pg. 369, 1988.
rat LD50 intravenous > 50mg/kg (50mg/kg) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

LUNGS, THORAX, OR RESPIRATION: DYSPNEA

SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE
Oyo Yakuri. Pharmacometrics. Vol. 36, Pg. 369, 1988.
rat LD50 oral 2210mg/kg (2210mg/kg) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)

SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION
Oyo Yakuri. Pharmacometrics. Vol. 36, Pg. 369, 1988.
rat LD50 subcutaneous > 100mg/kg (100mg/kg) SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" Oyo Yakuri. Pharmacometrics. Vol. 36, Pg. 369, 1988.
women TDLo oral 800ug/kg/2D-I (.8mg/kg) LUNGS, THORAX, OR RESPIRATION: COUGH

LUNGS, THORAX, OR RESPIRATION: PLEURAL EFFUSION
Pharmacotherapy Vol. 14, Pg. 119, 1993.
women TDLo oral 4400ug/kg/11D (4.4mg/kg) KIDNEY, URETER, AND BLADDER: OTHER CHANGES IN URINE COMPOSITION

LIVER: "HEPATITIS (HEPATOCELLULAR NECROSIS), DIFFUSE"

LIVER: "JAUNDICE, OTHER OR UNCLASSIFIED"
American Journal of Gastroenterology. Vol. 94, Pg. 1119, 1999.
women TDLo oral 24mg/kg/60D-I (24mg/kg) KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"

BLOOD: NORMOCYTIC ANEMIA
Postgraduate Medical Journal. Vol. 74, Pg. 416, 1998.
women TDLo oral 30mg/kg/10W-I (30mg/kg) BLOOD: EOSINOPHILIA

SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"

KIDNEY, URETER, AND BLADDER: INTERSTITIAL NEPHRITIS
American Journal of Medicine. Vol. 95, Pg. 248, 1993.
women TDLo oral 36400ug/kg/13 (36.4mg/kg) BRAIN AND COVERINGS: RECORDINGS FROM SPECIFIC AREAS OF CNS

SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE
Journal of Clinical Gastroenterology. Vol. 25, Pg. 718, 1997.

Post buying leads

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View